Core Viewpoint - Via Biotechnology (01873) experienced a significant stock price increase of over 20% following the release of its interim results for the six months ending June 30, 2025, with a reported share price of HKD 2.85 and a trading volume of HKD 49.03 million [1] Financial Performance - The company reported revenue of RMB 832 million, a year-on-year decrease of 15.27% [1] - Shareholder profit attributable to the company was RMB 122 million, reflecting a year-on-year increase of 4.28% [1] - Basic earnings per share were RMB 0.06 [1] - The gross profit margin improved to 40.8%, an increase of 6.3 percentage points compared to the same period last year, attributed to optimization of the Langhua business structure and enhanced operational efficiency in CRO business [1] AI Drug Development - Via Biotechnology has been investing in AI drug development for the past five years, with AI-related orders now accounting for 12% of new signed orders, indicating a growing trend [1] - According to Guojun International, significant transactions in AI drug development (AIDD) have occurred in the last five years, totaling over USD 50 billion [1] - The development of generative AI in pharmaceuticals emphasizes the importance of building leading model barriers over time, with efficiency in model development and training experience being crucial [1] - Collaborations with large pharmaceutical companies in AI research and development create a positive feedback loop in data and model construction, enhancing the competitive moat of leading firms [1]